Gemcitabine elaidate

Drug Profile

Gemcitabine elaidate

Alternative Names: CO-1.01; CO-101; CP-4126; Gemcitabine 5'-elaidic acid ester

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Clavis Pharma
  • Developer Clavis Pharma; Clovis Oncology
  • Class Antineoplastics; Deoxyribonucleosides; Esters; Pyrimidine nucleosides
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Feb 2013 Discontinued - Phase-I for Non-small cell lung cancer in United Kingdom (IV)
  • 15 Feb 2013 Discontinued - Phase-I for Non-small cell lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top